PRESS RELEASES

Date	Title
Oct 22, 2020	Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
Oct 22, 2020	Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
Oct 12, 2020	Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
Sep 15, 2020	Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Sep 8, 2020	Ardelyx to Participate in Three Upcoming Investor Conferences in September
Aug 6, 2020	Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Aug 3, 2020	Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
Jun 30, 2020	Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Jun 15, 2020	Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
Jun 9, 2020	Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com